Cannabis and cocaine remain the most commonly used illegal drugs across the European Union, but other substances, including synthetic drugs, are emerging as significant public health concerns, according to a joint report by the European Commission and the Organisation for Economic Co-operation and Development (OECD).
Nearly one in three Europeans have tried illegal drugs at some point, with younger populations showing notable usage patterns. Among young adults, 15% reported using cannabis in the past year, while 2.5% admitted to using cocaine. The highest rates of cannabis use were observed in the Czech Republic, Italy, France, and Spain, while Malta, Turkey, and Hungary reported the lowest. Similarly, cocaine use was most prevalent in the Netherlands, Spain, and Ireland and least common in Turkey, Portugal, Poland, and Hungary.
Regular drug use is linked to serious health risks, including cardiovascular disease, mental health disorders, accidents, and infectious diseases such as HIV, particularly among users of injectable drugs.
Drug Availability Unaffected by Penalties
Despite varying drug enforcement policies across EU member states, the availability of illegal substances remains largely unaffected, especially among young people. Sabrina Molinaro, an epidemiologist and research director at Italy’s National Research Council, emphasized that strict penalties often fail to target heavy users effectively.
“The major penalties impact only the people who use the substance once or fewer times in a year, so not the real heavy users,” Molinaro explained.
Molinaro, who coordinates the European School Survey Project on Alcohol and Other Drugs, noted that drug use trends among 16-year-olds have remained consistent over decades. For instance, while boys have historically been more likely to use cannabis, the gender gap has narrowed significantly, with some countries even reporting higher usage rates among girls.
Emerging Risks from Synthetic Drugs
While cannabis and cocaine dominate, other substances like MDMA (ecstasy), heroin, and synthetic drugs pose escalating risks. Synthetic drugs, including lab-manufactured cannabinoids and stimulants, are particularly concerning due to their unpredictable composition and potential for contamination.
“They are so dangerous because you don’t know what you are taking,” Molinaro warned, adding that these substances are often produced in substandard labs, increasing the risk of harmful pollutants.
In 2022, hundreds of synthetic drug labs were dismantled across the EU. The following year, the EU’s early warning system identified seven new synthetic opioid substances, underscoring the challenges authorities face in regulating these compounds swiftly.
“Synthetic opioids are a very big health issue in the adult population,” Molinaro said.
As drug usage trends continue to evolve, experts emphasize the need for robust monitoring, public awareness, and targeted interventions to mitigate the health risks associated with drug use across Europe.